Dr. Antonio Giordano, MD, Ph.D., ([ Ссылка ]) is President and Founder of the Sbarro Health Research Organization ([ Ссылка ]), which conducts research to diagnose, treat and cure cancer, but also has diversified into research beyond oncology, into the areas of cardiovascular disease, diabetes and other chronic illnesses.
Dr. Giordano is also a Professor of Molecular Biology at Temple University in Philadelphia, a 'Chiara fama' Professor in the Department of Pathology & Oncology at the University of Siena, Italy, and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, and the Center for Biotechnology, at Temple's College of Science & Technology.
In his research throughout the years, Dr. Giordano has identified numerous tumor suppressor genes, including Rb2/p130, which has been found to be active in lung, endometrial, brain, breast, liver and ovarian cancers, as well as interesting synergistic effects of gamma radiation in combination with this gene, accelerating the death of tumor cells.
Dr. Giordano went on to discover Cyclin A, Cdk9 (which is known to play critical roles in HIV transcriptions, inception of tumors, and cell differentiation), and Cdk10. Dr. Giordano also developed patented technologies for diagnosing cancer.
Dr. Giordano has published over 400 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology.
In 2011, Dr. Giordano and his team uncovered anti-tumor agents that might be effective in the treatment of mesothelioma, a cancer caused by prolonged asbestos exposure, by inducing cell death without harming healthy cells.
Dr. Giordano has been involved with many other fascinating programs, including digital health work to see if watching a computer animated avatar could assist women to lose weight, as well as analyzing the environmental relationship among toxic dumping and cancer growth, birth defects, and CNS disorders, due to the Camorra (the Neapolitan Mafia) illegally disposing of toxic waste.
